Free Trial

Cencora (COR) Stock Forecast & Price Target

Cencora logo
$242.11 +1.22 (+0.51%)
As of 01/17/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cencora - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
9

Based on 11 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 2 have given a hold rating, and 9 have given a buy rating for COR.

Consensus Price Target

$275.60
13.83% Upside
According to the 11 analysts' twelve-month price targets for Cencora, the average price target is $275.60. The highest price target for COR is $292.00, while the lowest price target for COR is $237.00. The average price target represents a forecasted upside of 13.83% from the current price of $242.11.
Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

Sign Up

COR Analyst Ratings Over Time

TypeCurrent Forecast
1/21/24 to 1/20/25
1 Month Ago
12/22/23 to 12/21/24
3 Months Ago
10/23/23 to 10/22/24
1 Year Ago
1/21/23 to 1/21/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$275.60$275.60$259.44$204.27
Forecasted Upside13.83% Upside21.04% Upside10.79% Upside-6.42% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cencora Stock vs. The Competition

TypeCencoraMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.82
2.52
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.83% Upside24,741.15% Upside12.44% Upside
News Sentiment Rating
Positive News

See Recent COR News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/13/2024Wells Fargo & Company
3 of 5 stars
 Lower TargetEqual Weight ➝ Equal Weight$249.00 ➝ $237.00+2.07%
12/4/2024Mizuho
2 of 5 stars
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Outperform$280.00+11.98%
11/7/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$287.00 ➝ $292.00+17.29%
11/7/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$275.00 ➝ $285.00+14.68%
11/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$263.00 ➝ $290.00+18.18%
11/7/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$250.00 ➝ $285.00+16.15%
10/7/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$277.00 ➝ $275.00+25.03%
9/18/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral$275.00 ➝ $245.00+4.46%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$280.00 ➝ $287.00+20.03%
4/30/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$265.00 ➝ $280.00+16.87%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/7/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$205.00 ➝ $215.00+15.07%
8/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$176.00 ➝ $190.00-1.69%
5/26/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/3/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$174.00 ➝ $182.00+8.81%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:57 PM ET.


Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 19, 2025. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • Cencora, Inc. has recently seen an increase in its stock price, currently trading at $237.74, indicating positive market sentiment and potential for further growth.
  • The company has received multiple upgrades from analysts, with price targets raised by firms like UBS Group and Barclays, suggesting strong confidence in its future performance.
  • Cencora, Inc. has a solid dividend payout, recently increasing its quarterly dividend to $0.55, which reflects a commitment to returning value to shareholders.
  • Analysts project significant earnings growth, with estimates for FY2025 earnings at $15.39 per share, indicating strong profitability potential.
  • Insider ownership stands at 15.80%, which can be a positive indicator of management's confidence in the company's future prospects.

Cencora
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • The company has a high debt-to-equity ratio of 4.84, which may indicate financial risk and could affect its ability to manage debt obligations effectively.
  • Despite recent upgrades, some analysts have issued hold ratings, suggesting that not all market participants are convinced of the stock's upside potential.
  • The stock has experienced fluctuations, with a one-year low of $214.77, indicating volatility that could deter risk-averse investors.
  • Cencora, Inc. has a current ratio of 0.88, which is below the ideal threshold of 1, suggesting potential liquidity issues in meeting short-term liabilities.
  • Recent insider selling, with 94,696 shares sold valued at over $22 million, may raise concerns about the confidence of insiders in the company's future performance.

COR Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $275.60, with a high forecast of $292.00 and a low forecast of $237.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 13.83% based on their 12-month stock forecasts.

Cencora has been rated by research analysts at Barclays, Evercore ISI, Mizuho, Robert W. Baird, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Cencora more than other "medical" companies. The consensus rating score for Cencora is 2.82 while the average consensus rating score for "medical" companies is 2.82. Learn more on how COR compares to other companies.


This page (NYSE:COR) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners